Rocatinlimab is a Monoclonal Antibody owned by Kyowa Kirin, and is involved in 8 clinical trials, of which 5 were completed, 2 are ongoing, and 1 is planned.

Rocatinlimab acts by antagonizing OX40. It is mainly expressed in activated Tcells. OX40-OX40 ligand interaction promotes the survival of activated T cells and accelerates the formation of memory T cells. OX40 also has an important role to play in the reactivation of memory T cells. KHK-4083 by antgonizing OX40, down regulates the inflammatory mediators and reduces the disease condition.

The revenue for Rocatinlimab is expected to reach a total of $2.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rocatinlimab NPV Report.

Rocatinlimab is originated and owned by Kyowa Kirin. Amgen is the other company associated in development or marketing of Rocatinlimab.

Rocatinlimab Overview

Rocatinlimab is under development for the treatment of atopic dermatitis. The drug candidate is a new molecular entity (NME). It is administered through intravenous and subcutaneous infusion. It is a monoclonal antibody and acts by targeting OX40. The drug candidate is based on POTELLIGENT antibody engineering technology. It was also under development for the treatment of moderate plaque psoriasis and ulcerative colitis .

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Rocatinlimab

Report Segments
  • Innovator
Drug Name
  • Rocatinlimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immunology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.